Volume 8.15 | Apr 24

Mammary Cell News 8.15 April 21, 2016
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
Newly Discovered Vulnerability in Breast Tumor Cells Points to Novel Treatment Approach Against Cancer
Investigators have found a way to attack a process that tumor cells use to escape the effects of standard cancer drugs. [Press release from Beth Israel Deaconess Medical Center discussing online publication in Nature Cell Biology] Press Release | Abstract
Culture and Characterize Human Mammary Epithelial Progenitors with Serum-Free EpiCult-B (Human) Free Protocols
PUBLICATIONS (Ranked by impact factor of the journal)

Induction of IL-25 Secretion from Tumor-Associated Fibroblasts Suppresses Mammary Tumor Metastasis
Scientists investigated the role of IL-25, an endogenous anticancer factor secreted from tumor-associated fibroblasts, in suppression of mouse 4T1 mammary tumor metastasis. [Nat Commun] Full Article

Sensitizing Basal-Like Breast Cancer to Chemotherapy Using Nanoparticles Conjugated with Interference Peptide
Researchers propose a novel therapeutic strategy using poly(glycidyl methacrylate) nanoparticles decorated with poly(acrylic acid) that enable dual delivery of docetaxel and interference peptides designed to block or inhibit engrailed 1. [Nanoscale] Abstract

Functional Interference in the Bone Marrow Microenvironment by Disseminated Breast Cancer Cells
The interaction between disseminated breast cancer cells and the bone marrow microenvironment which harbors them has not been addressed comprehensively. Employing advanced co-culture assays, proteomic studies, organotypic models as well as in vivo xenotransplant models, the authors define the consequences of this interaction on the stromal compartment of bone marrow, affected molecular pathways and subsequent effects on the hematopoietic stem and progenitor cells. [Stem Cells] Abstract

The Cellular Distribution of Na+/H+ Exchanger Regulatory Factor 1 Is Determined by the PDZ-I Domain and Regulates the Malignant Progression of Breast Cancer
A novel mutation, namely Na+/H+ exchanger regulatory factor 1 (NHERF1) Y24S, was identified in human breast cancer tissues and shown to correspond to a conserved residue in the PDZ-I domain of NHERF1. [Oncotarget] Full Article

Overexpression of Caspase 7 Is ERα Dependent to Affect Proliferation and Cell Growth in Breast Cancer Cells by Targeting p21(Cip)
Researchers showed that the caspase 7 (CASP7) expression is high in breast carcinoma tissues compared with normal counterpart. The ectopic expression of CASP7 was significantly associated with ERα expression status and persistently elevated in different stages of the breast tumor grades. [Oncogenesis] Full Article

Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway
Researchers report the synthesis and biological evaluation of imidazoles that induce apoptosis in breast cancer cells by negatively regulating PI3K/Akt/mTOR signaling pathway. [PLoS One] Full Article


A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients with Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial
PROTECT-2 was a confirmatory efficacy and safety study designed to compare proposed biosimilar LA-EP2006 with reference pegfilgrastim in early-stage breast cancer patients receiving adjuvant or neoadjuvant myelosuppressive chemotherapy. [Oncologist] Abstract | Full Article

Neratinib Plus Paclitaxel vs Trastuzumab plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial
Scientists determined whether neratinib, an irreversible pan-efficacious ERBB2 (formerly HER2 or HER2/neu) tyrosine kinase inhibitor, plus paclitaxel improves progression-free survival compared with trastuzumab plus paclitaxel in the first-line treatment of recurrent and/or metastatic ERBB2-positive breast cancer. [JAMA Oncol] Abstract

Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now
Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future
There is a well-known role of cell cycle dysregulation in breast cancer patients that is partly mediated by cyclin-dependent kinase (CDK) activity. Specific cyclin and CDK complexes regulate cell cycle progression by managing the transition through the cell cycle, and inhibition of CDKs represents an important target for novel agents. [Pharmacotherapy] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
National Cancer Centre Singapore, Singapore General Hospital and Clearbridge BioMedics Examine the Heterogeneity of CTCs in Breast Cancer Patients
The National Cancer Centre Singapore, Singapore General Hospital, and Clearbridge BioMedics have collaborated on a research project that examines circulating tumor cells from local breast cancer patients. Preliminary data from the study revealed heterogeneity in the circulating tumor cells (CTCs) isolated from each patient’s blood samples and tumor biopsy or surgical specimens. [Press release from Clearbridge BioMedics discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release

Penn Medicine Presents Evidence Showing New Drug Combination May Improve Outcomes for Women with Advanced Breast Cancer when Administered Before Surgery
Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. [Press release from Penn Medicine discussing research presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, New Orleans] Press Release

From our sponsor:
Webinar: Neural Stem Cell Culture Systems – Neurosphere vs. Adherent Monolayer Culture.
Watch now.
Hologic Announces FDA Clearance and Commercial Availability of the Affirm™ Prone Biopsy System
Hologic, Inc. announced the U.S. Food and Drug Administration (FDA) clearance and commercial launch of the Affirm™ prone biopsy system, the first dedicated prone biopsy system to offer both 2D and 3D™ imaging-guided breast biopsies. [Hologic, Inc.] Press Release

ImmunoBiochem Corporation Partners with the Centre for the Commercialization of Antibodies and Biologics at the University of Toronto to Advance New Antibody Drug Conjugates
ImmunoBiochem Corporation, a Canadian biopharmaceutical company developing novel Antibody Drug Conjugates, and the Centre for the Commercialization of Antibodies and Biologics have partnered to develop new therapeutics for the treatment of breast cancer and other solid tumors. [ImmunoBiochem Corporation (PR Newswire Association LLC.)] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Worldwide Innovative Networking in Personalized Cancer Medicine (WIN) 2016
June 27-28, 2016
Paris, France

NEW UK Breast Cancer Research Symposium 2016
July 22-23, 2016
London, United Kingdom

Visit our events page to see a complete list of events in the mammary cell community.
NEW Clinical Scientist – Endocrine Therapy in Breast Cancer (Royal College of Surgeons in Ireland)

Scientist – Cancer Research (Institute of Clinical Physiology)

Postdoctoral Fellow – Metastatic Reactivation of Cancer (MD Anderson Cancer Center)

Faculty Position – Cancer Immunology (University of New Mexico)

Faculty Position – Cancer Research (Eppley Institute for Research in Cancer)

Postdoctoral Fellow – Breast Cancer (Northwestern University)

Faculty Position – Tumor Immunology (John Wayne Cancer Institute at Providence Saint John’s Health Center)

Postdoctoral Fellow – Noncoding RNAs in Breast Cancer (University of Texas MD Anderson Cancer Center)

Postdoctoral Fellow – Breast and Ovarian Cancer (Johns Hopkins University School of Medicine)

PhD Fellowship – Breast Cancer (INCLIVA Health Research Institute)

Postdoctoral Fellowship – Platelets in Metastatic Breast and Colon Cancer (Université de Strasbourg)

Research Associate – Breast Cancer and Huntington’s Disease (University of Pittsburgh Drug Discovery Institute)

Postdoctoral Fellowship – Tumor Biology of Breast and Lung Cancer (Cold Spring Harbor Laboratory)

Postdoctoral Fellowship – Microenvironment of Breast Cancer (Icahn School of Medicine)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Clinical Pathways Associate – Cancer Therapeutics (Fred Hutchinson Cancer Research Center)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us